SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Pauls Dietrich John

(Last) (First) (Middle)
2 CARLSON PARKWAY
SUITE 260

(Street)
MINNEAPOLIS MN 55447

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
12/06/2018
3. Issuer Name and Ticker or Trading Symbol
DiaMedica Therapeutics Inc. [ DMAC ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Voting Common Shares, no par value per share 24,804(1) D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) (2) 10/06/2021 Voting Common Shares 10,000 $17.31(3) D
Stock Option (right to buy) (4) 02/15/2022 Voting Common Shares 10,000 $25.58(3) D
Stock Option (right to buy) (5) 06/25/2023 Voting Common Shares 10,000 $16.1(3) D
Stock Option (right to buy) (6) 12/01/2025 Voting Common Shares 67,500 $2.26(3) D
Stock Option (right to buy) (7) 11/28/2026 Voting Common Shares 42,500 $3.91(3) D
Stock Option (right to buy) (8) 06/19/2027 Voting Common Shares 42,500 $4.82(3) D
Stock Option (right to buy) (9) 04/17/2028 Voting Common Shares 33,500 $8.43(3) D
Warrant (10) 03/28/2020 Voting Common Shares 2,050 $7 D
Explanation of Responses:
1. Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan.
2. This stock option vests in 12 equal quarterly installments over three years starting on January 6, 2012.
3. Represents the conversion of the exercise price from CAD$ to US$ on November 30, 2018.
4. This stock option vests in 12 equal quarterly installments over three years starting on May 15, 2012.
5. This stock option vests in 12 equal quarterly installments over three years starting on September 25, 2013.
6. This stock option vests in 12 equal quarterly installments over three years starting on March 1, 2016.
7. This stock option vests in 12 equal quarterly installments over three years starting on February 28, 2017.
8. This stock option vests in 12 equal quarterly installments over three years starting on September 19, 2017.
9. This stock option vests in 12 equal quarterly installments over three years starting on July 17, 2018.
10. This warrant is fully vested.
/s/ Amy Culbert, attorney-in-fact 12/06/2018
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.